Barclays PLC Novavax Inc Call Options Transaction History

Barclays PLC

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$3.76 - $6.02 $1.69 Million - $2.71 Million	-450,000 Reduced 90.0%	50,000 $239,000
Q4 2023 Feb 15, 2024	BUY	$4.8 - $7.67 $2.4 Million - $3.84 Million	500,000 New	500,000 $2.4 Million
Q1 2023 May 04, 2023	BUY	$5.76 - $12.48 $3.6 Million - $7.8 Million	625,000 Added 357.14%	800,000 $5.54 Million
Q4 2022 Feb 13, 2023	BUY	$8.86 - $25.04 $1.55 Million - $4.38 Million	175,000 New	175,000 $1.8 Million
Q4 2021 Feb 14, 2022	BUY	$134.56 - $217.97 $19.3 Million - $31.3 Million	143,500 Added 643.5%	165,800 $23.7 Million
Q3 2021 Nov 09, 2021	SELL	$177.8 - $270.58 $21.5 Million - $32.7 Million	-120,800 Reduced 84.42%	22,300 $4.62 Million
Q2 2021 Aug 13, 2021	BUY	$121.0 - $257.67 $14.9 Million - $31.7 Million	123,100 Added 615.5%	143,100 $30.4 Million
Q1 2021 May 13, 2021	BUY	$112.98 - $319.93 $1.65 Million - $4.67 Million	14,600 Added 270.37%	20,000 $3.63 Million
Q4 2020 Feb 11, 2021	SELL	$78.74 - $139.5 $771,652 - $1.37 Million	-9,800 Reduced 64.47%	5,400 $602,000
Q3 2020 Nov 12, 2020	BUY	$79.44 - $178.51 $313,788 - $705,114	3,950 Added 35.11%	15,200 $1.65 Million
Q2 2019 Aug 14, 2019	BUY	$4.93 - $12.2 $55,462 - $137,250	11,250 New	11,250 $66,000

290

93.4M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $680M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.